Medistim ASA

OM:MEDIO Stock Report

Market Cap: NOK 2.9b

Medistim Management

Management criteria checks 2/4

Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 15.25 years. total yearly compensation is NOK7.21M, comprised of 42% salary and 58% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth NOK11.01M. The average tenure of the management team and the board of directors is 10 years and 1.9 years respectively.

Key information

Kari Krogstad

Chief executive officer

NOK 7.2m

Total compensation

CEO salary percentage42.0%
CEO tenure15.3yrs
CEO ownership0.4%
Management average tenure10yrs
Board average tenure1.9yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Kari Krogstad's remuneration changed compared to Medistim's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NOK 102m

Jun 30 2024n/an/a

NOK 104m

Mar 31 2024n/an/a

NOK 103m

Dec 31 2023NOK 7mNOK 3m

NOK 104m

Sep 30 2023n/an/a

NOK 117m

Jun 30 2023n/an/a

NOK 116m

Mar 31 2023n/an/a

NOK 116m

Dec 31 2022NOK 9mNOK 3m

NOK 114m

Sep 30 2022n/an/a

NOK 98m

Jun 30 2022n/an/a

NOK 92m

Mar 31 2022n/an/a

NOK 93m

Dec 31 2021NOK 6mNOK 3m

NOK 91m

Sep 30 2021n/an/a

NOK 88m

Jun 30 2021n/an/a

NOK 84m

Mar 31 2021n/an/a

NOK 70m

Dec 31 2020NOK 6mNOK 3m

NOK 69m

Sep 30 2020n/an/a

NOK 71m

Jun 30 2020n/an/a

NOK 74m

Mar 31 2020n/an/a

NOK 75m

Dec 31 2019NOK 4mNOK 3m

NOK 70m

Sep 30 2019n/an/a

NOK 79m

Jun 30 2019n/an/a

NOK 73m

Mar 31 2019n/an/a

NOK 64m

Dec 31 2018NOK 4mNOK 2m

NOK 57m

Sep 30 2018n/an/a

NOK 46m

Jun 30 2018n/an/a

NOK 48m

Mar 31 2018n/an/a

NOK 45m

Dec 31 2017NOK 4mNOK 2m

NOK 48m

Compensation vs Market: Kari's total compensation ($USD636.05K) is above average for companies of similar size in the Swedish market ($USD453.45K).

Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.

CEO

Kari Krogstad (60 yo)

15.3yrs

Tenure

NOK 7,205,702

Compensation

Ms. Kari Eian Krogstad serves as Independent Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President...

Leadership Team

NamePositionTenureCompensationOwnership
Kari Krogstad
CEO & President15.3yrsNOK 7.21m0.39%
NOK 11.0m
Thomas Jakobsen
Chief Financial Officerno dataNOK 2.77m0.17%
NOK 4.8m
Helge Borslid
Vice President of Operationsno dataNOK 1.67mno data
Hæge Johanne Wetterhus
Vice President of Marketing14.3yrsNOK 1.87m0.0087%
NOK 248.3k
Hakon Grothe
Chief Innovation Officer5.7yrsNOK 1.91m0.043%
NOK 1.2m
Ole Eiksund
Chief Business Development Officer2.7yrsNOK 1.68m0.032%
NOK 916.0k
Mike Farbelow
President of Medistim USA Incno dataNOK 3.63mno data
Roger Morberg
Vice President of Sales - APACno dataNOK 2.55m0.089%
NOK 2.5m
Stephanie Stenhagen
Vice President of Sales EMEAno dataNOK 1.79m0.015%
NOK 434.3k
Ole Robsrud
Managing Director of Medistim Norge ASno dataNOK 1.83m0.019%
NOK 536.8k

10.0yrs

Average Tenure

60yo

Average Age

Experienced Management: MEDIO's management team is seasoned and experienced (10 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Oyvin Broymer
Chairman24.9yrsNOK 495.00k7.02%
NOK 200.5m
Anna Ahlberg
Independent Director1.7yrsno datano data
Jon Hoem
Independent Director1.9yrsno datano data
Ole Dahlberg
Independent Director1.7yrsno datano data
Tove Raanes
Independent Director10.9yrsNOK 300.00k0.011%
NOK 310.6k
Peder Strand
Directorno datano datano data
Gry Dahle
Directorno datano datano data

1.9yrs

Average Tenure

54yo

Average Age

Experienced Board: MEDIO's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:00
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medistim ASA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Magnus GranerødBeringer Finance AB
Karl NorénDanske Bank
Simen MortensenDNB Markets